4,5-Di-t-butylpyridazine | 124840-89-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4,5-Di-t-butylpyridazine
• 英文别名: 4,5-ditert-butylpyridazine
• CAS: 124840-89-7
• 化学式: C₁₂H₂₀N₂
• 分子量: 192.304
• InChiKey: POMQIBSXIHJREU-UHFFFAOYSA-N

物化性质

• 熔点：
  109 °C(Solv: hexane (110-54-3))
• 沸点：
  289.4±9.0 °C(Predicted)
• 密度：
  0.918±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  3,4-di-t-butylthiophene 1,1-dioxide 在 氢氧化钾 作用下， 以 甲醇 、 甲苯 为溶剂， 反应 8.0h， 生成 4,5-Di-t-butylpyridazine
  参考文献：
  名称：

  带有顺式取向的两个叔丁基的空间位阻环烯烃的合成与性质。2,3-二叔丁基双环[2.2.2]辛-2-烯衍生物

  摘要：

  Le 1,1-dioxyde du 3,4-di-t-butylthiophene reagit avec divers composesvinyliques pour donner des composes benzeniques, desheterocycles et un indane, steriquement encombres

  DOI：

  10.1021/ja00177a028

文献信息

• HETEROCYCLIC PYRIDONE COMPOUND, AND INTERMEDIATE, PREPARATION METHOD AND USE THEREOF
  申请人：Cheng Jianjun

  公开号：US20140206679A1

  公开（公告）日：2014-07-24

  The present invention relates to a heterocyclic pyridone compound represented by General Formula (I), where the heterocyclic pyridone compound is used as a tyrosine kinase inhibitor, and particularly a c-Met inhibitor. The present invention also relates to intermediates for preparing heterocyclic pyridone compound and a preparation method. The present invention further relates to a pharmaceutical composition containing the heterocyclic pyridone compound as an active ingredient, and a use of the pharmaceutical composition in treatment of diseases associated with tyrosine kinase c-Met, especially cancer associated with c-Met, as a medicament.

  本发明涉及一种由通式(I)表示的杂环吡啶酮化合物，其中该杂环吡啶酮化合物用作酪氨酸激酶抑制剂，特别是c-Met抑制剂。本发明还涉及用于制备杂环吡啶酮化合物的中间体和制备方法。本发明还涉及一种包含杂环吡啶酮化合物作为活性成分的药物组合物，以及药物组合物在治疗与酪氨酸激酶c-Met相关的疾病，特别是与c-Met相关的癌症作为药物的用途。
• CATALYST FOR CROSS-COUPLING REACTION, AND PROCESS FOR PRODUCTION OF AROMATIC COMPOUND USING THE SAME
  申请人：Nakamura Masaharu

  公开号：US20110152523A1

  公开（公告）日：2011-06-23

  The present invention provides a process for efficiently producing an alkylated aromatic compound in good yield, by a cross-coupling reaction between an alkyl halide and an aromatic magnesium reagent. A process for producing an aromatic compound represented by Formula (1): R—Ar′  (1) wherein R is a hydrocarbon group, and Ar′ is an aryl group; the process comprising: reacting a compound represented by Formula (2): R—X  (2) wherein X is a halogen atom, and R is as defined above, with a magnesium reagent represented by Formula (3): Ar′—MgY  (3) wherein Y is a halogen atom, and Ar′ is as defined above, in the presence of a catalyst for cross-coupling reactions comprising an iron compound and a bisphosphine compound represented by Formula (4): wherein Q is a divalent group derived from an aromatic ring by removing two hydrogen (H) atoms on adjacent carbon atoms; and each Ar is independently an aryl group.

  本发明提供了一种高效产生烷基芳香化合物的方法，通过烷基卤化物和芳香镁试剂之间的交叉偶联反应，以良好的产率产生烷基芳香化合物的方法，所述方法包括：将由式（2）表示的化合物：R—X（2）其中X是卤素原子，R如上所定义，与由式（3）表示的镁试剂：Ar′—MgY（3）其中Y是卤素原子，Ar′如上所定义，在交叉偶联反应的催化剂存在下反应，所述催化剂包括一种铁化合物和一种由式（4）表示的双膦化合物：其中Q是通过去除相邻碳原子上的两个氢（H）原子从芳香环中衍生的二价基团；每个Ar都是独立的芳基团。
• Bicyclic And Tricyclic Compounds As KAT II Inhibitors
  申请人：Claffey Michelle M.

  公开号：US20100324043A1

  公开（公告）日：2010-12-23

  Compounds of Formula X: wherein A, X, Y, Z, R 5 , R 6a , and R 6b are as defined herein, and pharmaceutically acceptable salts thereof, are described as useful for the treatment of cognitive deficits associated with schizophrenia and other neurodegenerative and/or neurological disorders in mammals, including humans.

  化合物X的结构如下：其中A、X、Y、Z、R5、R6a和R6b的定义如本文所述，并且其药用盐被描述为用于治疗与精神分裂症及其他哺乳动物，包括人类，相关的认知缺陷的化合物，以及其他神经退行性和/或神经系统疾病。
• Bicyclic And Tricyclic Derivatives As Thrombin Receptor Antagonists
  申请人：Chackalamannil Samuel

  公开号：US20080090830A1

  公开（公告）日：2008-04-17

  Heterocyclic-substituted tricyclics of the formula or a pharmaceutically acceptable salt or solvate of said compound, isomer or racemic mixture wherein represents an optional double bonds the dotted line is optionally a bond or no bonds resulting in a double bond or a single bond, as permitted by the valency requirement and wherein E, A, G M, Het, B, X, R 3 , R 10 , R 11 , R 32 and R 33 are herein defined and the remaining substituents are as defined in the specification, are disclosed, as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failures and cancer by administering said compounds. Combination therapy with other cardiovascular agents is also claimed.

  具有以下结构的杂环取代的三环化合物，或者该化合物的药用盐或溶剂化合物、异构体或消旋混合物，其中表示一个可选的双键，虚线可以是一个键或无键，从而形成一个双键或一个单键，符合化合价要求，E、A、G、M、Het、B、X、R3、R10、R11、R32和R33在此有定义，其余取代基如规范中所定义，以及含有它们的药物组合物和通过给予该化合物治疗与血栓形成、动脉粥样硬化、再狭窄、高血压、心绞痛、心律失常、心力衰竭和癌症相关的疾病的方法。还声称与其他心血管药物的联合疗法。
• NOVEL INDOLE DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS)
  申请人：Lanter James C.

  公开号：US20090216023A1

  公开（公告）日：2009-08-27

  The present invention is directed to novel indole derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders and conditions modulated by the androgen receptor.

  本发明涉及新型吲哚衍生物，包含它们的药物组合物以及它们在治疗由雄激素受体调节的疾病和症状中的应用。